Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | XBP1 | P17861 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13206417 | 0.89 | ALOX15 (0.40) | MCL1TP53ALOX15MAPK1HPGD | |
| SCHEMBL1120133 | 0.85 | MCL1 (0.42) | MCL1TP53ALOX15MAPK1MEN1 | |
| SCHEMBL15271359 | 0.77 | TP53 (0.37) | MCL1TP53ALOX15MAPK1MEN1 | |
| SCHEMBL30442982 | 0.71 | ALOX15 (0.43) | MCL1TP53ALOX15MAPK1MAPT | |
| SCHEMBL5086281 | 0.71 | HCAR2 (0.42) | HPGD | |
| Lithium SCHEMBL31258223 | 0.70 | ALOX15 (0.42) | TP53ALOX15MAPK1HPGDHSD17B10 | |
| Lithium Ion SCHEMBL31258235 | 0.69 | MEN1 (0.33) | MCL1TP53ALOX15MAPK1MEN1 | |
| SCHEMBL22327730 | 0.67 | HPGD (0.44) | TP53ALOX15MAPK1MEN1MAPT | |
| SCHEMBL28965148 | 0.60 | HPGD (0.44) | MEN1HPGDKMT2ASMN1; SMN2 | |
| SCHEMBL1833402 | 0.60 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110184188-A1 | Insecticidal Benzenedicarboxamide Derivative | BAYER CROPSCIENCE AG (DE) | 2011-07-28 | — | — | US | disclosed |
| EP-2318374-A2 | INSECTICIDAL BENZENEDICARBOXAMIDE DERIVATIVE | Bayer CropScience AG (DE) | 2011-05-11 | — | — | EP | disclosed |
| WO-2010094406-A1 | AMINOPYRIMIDINAMIDES AS PEST CONTROL AGENTS | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2010-08-26 | — | — | WO | disclosed |
| WO-2010012442-A2 | INSECTICIDAL BENZENEDICARBOXAMIDE DERIVATIVE | BAYER CROPSCIENCE AG (DE) | 2010-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110184188-A1 | Insecticidal Benzenedicarboxamide Derivative | DDT, BRD9, BCL2A1 | MCL1 1389/4885TP53 4156/4885ALOX15 3948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.